Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Wednesday, April 2, 2025 · 799,409,274 Articles · 3+ Million Readers

Renowned Biomedical Scientist Franco Cavaleri Challenges Conventional Alzheimer's Theories in Groundbreaking Study

/EIN News/ -- VANCOUVER, British Columbia, March 31, 2025 (GLOBE NEWSWIRE) -- Franco Cavaleri, B.Sc., Ph.D.c, a distinguished biomedical research scientist and CEO of Biologic Pharmamedical Research and Manufacturing, has published a pioneering study that reexamines the role of amyloid β-peptides (Aβ) in Alzheimer's disease (AD). This research, featured in Frontiers in Neuroscience, proposes a paradigm shift in understanding the function of Aβ, suggesting they may serve a protective role against metal toxicity in the brain rather than being primary culprits in AD progression.​

A Protective Perspective on Amyloid β-Peptides

Alzheimer's disease has long been associated with the accumulation of amyloid plaques, leading to the prevailing belief that Aβ contributes directly to neurodegeneration. Cavaleri's study challenges this notion by presenting evidence that Aβ and the enzyme β-secretase (BACE1) are integral to a cellular defense mechanism aimed at sequestering harmful metal ions. This chelation process may prevent oxidative stress and neuronal damage by neutralizing metal-induced toxicity. It is only when this protective system becomes overwhelmed by excessive metal exposure that neurodegenerative symptoms emerge.

Implications for Alzheimer's Research and Treatment

This groundbreaking perspective opens new avenues for Alzheimer's research, emphasizing the need to explore environmental factors, such as metal exposure, in disease development. By shifting the focus from solely targeting Aβ for therapeutic intervention to understanding its protective functions, scientists can develop more effective strategies that address the root causes of neurodegeneration.​

Franco Cavaleri: A Leader in Biomedical Innovation

Franco Cavaleri's extensive background in nutritional biochemistry and natural medicine pharmacology has positioned him at the forefront of biomedical research. As CEO and Research Director of Biologic Pharmamedical Research and Manufacturing, Cavaleri has dedicated his career to bridging the gap between natural health products and pharmaceutical science. His work has led to significant advancements in understanding inflammation, neurodegenerative diseases, and the pharmacology of natural compounds. ​

Beyond his groundbreaking research, Franco Cavaleri is the best-selling author and host of the Potential Within podcast, and a former IFBB Mr. North America Bodybuilding Champion. His powerful personal story—overcoming severe ulcerative colitis without surgery through targeted natural medicine and science-backed supplementation—fuels his mission to transform modern health care. Through innovations like his patented Curcumin BioBDMC30™, Ashwith™ Ashwagandha, Keto BHB-BA™, and Glyvia™ sweetener (among over 15 other patents), Cavaleri is redefining what proactive health looks like. His integrative approach fuses rigorous biomedical science with holistic lifestyle and nutraceutical interventions, offering a sustainable solution to an overburdened healthcare system. By empowering individuals to take control of their health through nutrition, precision supplementation, and evidence-based self-care, Cavaleri’s work aims not only to reduce dependency on conventional medicine—but to enable longer, healthier, and more vibrant lives.

About Biologic Pharmamedical Research and Manufacturing

Biologic Pharmamedical Research and Manufacturing, based in Vancouver, Canada with manufacturing facilities in both Canada and the USA, specializes in the research and development of evidence-based nutraceuticals and pharmaceuticals. Under Cavaleri's leadership, the company focuses on innovative solutions that merge natural medicine with modern pharmacological principles to address complex health challenges as well as prevention. ​BiologicPharmaMedical

Access the Full Study

For a comprehensive understanding of this transformative research, the full study is available at Frontiers in Neurology.

Media Contact

Christina Weizmann
Communications Lead
Phone: 604.684.9321
Email: christina.w@biologic-med.com

Business Development Contact

Mike Schmidt
VP Business & Product Development
Phone: 1.855.518.8858
Email: info@biologicpharmamedical.com


Primary Logo

Powered by EIN News

Distribution channels: Healthcare & Pharmaceuticals Industry, Technology ...

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Submit your press release